Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302859 | 0.84 | CHRNA1 (0.34) | ALDH1A1TSHR | |
| SCHEMBL16346007 | 0.84 | S1PR1 (0.39) | ALDH1A1LMNATSHRTRPA1PTGS1 | |
| SCHEMBL15017386 | 0.82 | AKR1C3 (0.35) | ALDH1A1TSHRPTGS1 | |
| SCHEMBL4621988 | 0.82 | S1PR1 (0.38) | ALDH1A1TYR | |
| SCHEMBL16415970 | 0.80 | SLC6A2 (0.43) | ALDH1A1LMNATSHR | |
| SCHEMBL16212392 | 0.80 | GAA (0.38) | ALDH1A1TSHR | |
| SCHEMBL2556425 | 0.78 | TDP1 (0.39) | ALDH1A1LMNATP53TDP1TSHR | |
| SCHEMBL4338371 | 0.77 | ALDH1A1 (0.49) | ALDH1A1LMNATDP1TSHR | |
| SCHEMBL22440024 | 0.77 | ALDH1A1 (0.49) | ALDH1A1LMNATDP1TSHR | |
| SCHEMBL12614866 | 0.77 | MAPT (0.46) | ALDH1A1LMNATSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
| EP-2991983-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014177458-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| EP-2403840-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | Pierre Fabre Médicament (FR) | 2012-01-11 | — | — | EP | disclosed |
| EP-2265606-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010100139-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009129109-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-1381363-A1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002092086-A1 | IMIDAZO (1,2-A)-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |